Skip to main content
. 2024 Mar 13;12(3):e008638. doi: 10.1136/jitc-2023-008638

Figure 1.

Figure 1

(A) Swimmer plot of patients who received nivolumab. Each lane represents an individual patient’s tumor type, best objective response, sex, age, and treatment duration. (B) Progression-free survival of patients based on the RECIST criteria response. PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.